Results 21 to 30 of about 9,243 (198)
PLoS ONE, 2022 Background Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable.
Seokwoo Park +4 more
doaj +3 more sources
Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
Pharmaceuticals, 2018 The paper addresses the safety of febuxostat and summarizes reports on side effects and interactions of febuxostat published by the cut-off date (last day of literature search) of 20 March 2018.
Andreas Jordan, Ursula Gresser
doaj +1 more source
, 2008 INTRODUCTION: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years. METHODS AND OUTCOMES:We conducted a systematic review and aimed to answer the following clinical questions: What are the
Underwood, Martin
core +3 more sources
Febuxostat: a new drug for an old disease. Do we really need it?
Italian Journal of Medicine, 2013 BACKGROUND Febuxostat is a non-purine selective inhibitor of xanthine oxidase whose therapeutic effect is decreasing the serum uric acid concentration.
Giovanni Gulli, Luigi de Filippis
doaj +1 more source
The role of urate and xanthine oxidase in vascular oxidative stress:Future directions [PDF]
, 2009 Vascular oxidative stress has been shown to be a potent factor in the pathophysiology of endothelial dysfunction. Despite current optimal evidence-based therapy, mortality from various cardiovascular disorders remains high.
George, Jacob, Struthers, Allan
core +5 more sources
Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity [PDF]
, 2014 Aims Obesity is a risk factor for diabetes and cardiovascular diseases, with the incidence of these disorders becoming epidemic. Pathogenic responses to obesity have been ascribed to adipose tissue (AT) dysfunction that promotes bioactive mediator ...
Baust, Jeff +14 more
core +1 more source
The current treatment strategy for gouty arthritis
Современная ревматология, 2018 Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA).
M. S. Petrova +2 more
doaj +1 more source
Scientific Reports, 2023 Hyperuricemia relates to chronic kidney disease (CKD) progression and impaired endothelial function. Febuxostat is potent and effective for decreasing serum uric acid levels.
Naowanit Nata +4 more
doaj +1 more source
Indian Journal of Pain, 2015 Background: Allopurinol and febuxostat are xanthine oxidase inhibitors which are used in the treatment of hyperuricemia and gout. Pain is one of the important symptoms in gout patients.
Promod D Shankpal +4 more
doaj +1 more source
Pharmacology and clinical drug candidates in redox medicine [PDF]
, 2015 SIGNIFICANCE Oxidative stress is suggested to be a disease mechanism common to a wide range of disorders affecting human health. However, so far, the pharmacotherapeutic exploitation of this, for example, based on chemical scavenging of pro-oxidant ...
Casas, Ana I +11 more
core +2 more sources